Managing anemia in lymphoma and multiple myeloma

Gunnar BirgegårdDepartment of Haematology, University HospitalUppsala, SwedenCorrespondencegunnar.birgegå[email protected]

Pages 527-539 | Published online: 11 Apr 2008

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

AuerbachMBallardHTroutJRIntravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trialJ Clin Oncol2004221301715051778
PubMed Web of Science ®Google Scholar
Barrett-LeePJLudwigHBirgegårdGIndependent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anemia SurveyOncology200670344816493206
PubMed Web of Science ®Google Scholar
BeguinYPrediction of response to treatment with recombinant human erythropoietin in anemia associated with cancerMed Oncol199815Suppl 1S38469785336
PubMedGoogle Scholar
BirgegårdGAaproMSBokemeyerCCancer-related anemia: pathogenesis, prevalence and treatmentOncology200568Suppl 131115855811
PubMed Web of Science ®Google Scholar
BirgegårdGGascónPLudwigHEvaluation of anemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anemia SurveyEur J Haematol2006773788617044835
PubMed Web of Science ®Google Scholar
BirgegårdGDahlFGlimeliusBEvaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatmentMed Oncol2007243182217873308
PubMed Web of Science ®Google Scholar
BohliusJWilsonJSeidenfeldJRecombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patientsJ Natl Cancer Inst2006a987081416705125
PubMed Web of Science ®Google Scholar
BohliusJWeingartOTrelleSCancer-related anemia and recombinant human erythropoietin – an updated overviewNat Clin Pract Oncol2006b31526416520805
PubMedGoogle Scholar
BokemeyerCAaproMSCourdiAEORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancerEur J Cancer20044022011615454245
PubMed Web of Science ®Google Scholar
BokemeyerCAaproMSCourdiAEuropean Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the ElderlyEORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 updateEur J Cancer2007432587017182241
PubMed Web of Science ®Google Scholar
CasadevallNNatafJVironBPure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietinN Eng J Med200234646975
PubMed Web of Science ®Google Scholar
CavillIAuerbachMBailieGRIron and the anemia of chronic diseaseCurr Med Res Opin2006227313716684434
PubMed Web of Science ®Google Scholar
CazzolaMPonchioLPedrottiCPrediction of response to recombinant human erythropoietin in anemia of malignancyHematologica19968143441
PubMed Web of Science ®Google Scholar
CellaDThe Functional Assessment of Cancer-Therapy Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigueSemin Hematol19973413199253779
PubMed Web of Science ®Google Scholar
CellaDThe effects of anemia and anemia treatment on the quality of life of people with cancerOncology (Williston Park)2002169 Suppl 101253212380962
PubMed Web of Science ®Google Scholar
CellaDDobrezDGlaspyJControl of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomesAnn Oncol2003a145111912649095
PubMed Web of Science ®Google Scholar
CellaDZagariMJVandorosCEpoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general populationJ Clin Oncol2003b213667312525531
PubMed Web of Science ®Google Scholar
CoiffierBGuastallaJPPujade-LauraineEAnemia Study GroupPredicting cancer-associated anemia in patients receiving non-platinum chemotherapyEur J Cancer20013716172311527686
PubMed Web of Science ®Google Scholar
CrawfordJCellaDCleelandCSRelationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapyCancer2002958889512209734
PubMed Web of Science ®Google Scholar
DammaccoFCastoldiGRödjerSEfficacy of epoetin alfa in the treatment of anemia of multiple myelomaBr J Haematol2001113172911328297
PubMed Web of Science ®Google Scholar
DemetriGDKrisMWadeJQuality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study GroupJ Clin Oncol1998163412259779721
PubMed Web of Science ®Google Scholar
DjulbegovicBErythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelinesBest Pract Res Clin Haematol2005184556615792920
PubMed Web of Science ®Google Scholar
ElliottSBusseLBassMBAnti-Epo receptor anitbodies do not predict Epo receptor expressionBlood20061071892516249375
PubMed Web of Science ®Google Scholar
FallowfieldLGagnonDZagariMfor the Epoetin Alfa Study GroupMultivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapyBr J Cancer20028713415312454760
PubMed Web of Science ®Google Scholar
FaquinWCSchneiderTJGoldbergMAEffect of inflammatory cytokines on hypoxia-induced erythropoietin productionBlood1992791987941373333
PubMed Web of Science ®Google Scholar
FishbaneSFreiGLMaesakaJReduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementationAm J Kidney Dis1995264167611266
PubMed Web of Science ®Google Scholar
FishbaneSGalganoSLangleyRCJrReticulocyte hemoglobin content in the evaluation or iron status of hemodialysis patientsKidney Int199752217229211366
PubMed Web of Science ®Google Scholar
FranckSLinssenJMessingerMPotential utility of Ret-Y in the diagnosis of iron restricted erythropoiesisClin Chem2004501240215229154
PubMed Web of Science ®Google Scholar
GabriloveJLCleelandCSLivingstonRBClinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosingJ Clin Oncol20011928758211387360
PubMed Web of Science ®Google Scholar
GlaspyJBukowskiRSteinbergDImpact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study GroupJ Clin Oncol1997151218349060566
PubMed Web of Science ®Google Scholar
GroopmanJEItriLMChemotherapy-induced anemia in adults: incidence and treatmentJ Natl Cancer Inst19999116163410511589
PubMed Web of Science ®Google Scholar
HagbergABarbanyGLandegrenUBeta-globin mRNA increases rapidly during erythropoietin treatmentScand J Clin Lab Invest2003632394512817911
PubMed Web of Science ®Google Scholar
HedenusMAdrianssonMMiguelJSEfficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled studyBr J Haematol200312239440312877666
PubMed Web of Science ®Google Scholar
HedenusMBirgegårdGNäsmanPAddition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter studyLeukemia2007216273217252006
PubMed Web of Science ®Google Scholar
HenkeMLaszigRRübeCErythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialLancet2003362939212556014575968
PubMed Web of Science ®Google Scholar
HenryDAbelsRLarholtKPrediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-alpha) therapy in cancer patientsBlood1995851676787888686
PubMed Web of Science ®Google Scholar
HenryDHDahlNVAuerbachMIntravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapyOncologist2007122314217296819
PubMed Web of Science ®Google Scholar
HeskethPJArenaFPatelDA randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have non-myeloid malignanciesCancer20041008596814770445
PubMed Web of Science ®Google Scholar
KatodritouESpeletasMPrediction of response of anemia to recombinant human erythropoietin in patients with multiple my eloma and lymphomaHematol J20045suppl 2191
Google Scholar
KatodritouETerposEZervasKHypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphomaAnn Hematol2007863697617375302
PubMed Web of Science ®Google Scholar
KyleRAMultiple myeloma: review of 869 casesMayo Clin Proc19755029401110582
PubMed Web of Science ®Google Scholar
Leyland-JonesBSemiglazovVPawlickiMMaintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival studyJ Clin Oncol20052359607216087945
PubMed Web of Science ®Google Scholar
LittlewoodTJBajettaENortierJWEpoetin Alfa Study GroupEffects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trialJ Clin Oncol20011928657411387359
PubMed Web of Science ®Google Scholar
LudwigHStrasserKSymptomatology of anemiaSemin Oncol2001282 Suppl 871411395846
PubMed Web of Science ®Google Scholar
LudwigHVan BelleSBarrett-LeePThe European Cancer Anemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patientsEur J Cancer200440229330615454256
PubMed Web of Science ®Google Scholar
LymanGHGlaspyJAre there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic reviewCancer20061062233316331597
PubMed Web of Science ®Google Scholar
MacdougallICTuckerBThompsonJA randomized controlled study of iron supplementation in patients treated with erythropoietinKidney Int1996501694998914038
PubMed Web of Science ®Google Scholar
MacdougallIMerits of percentage of hypochromic red cells as a marker of functional iron deficiencyNephrol Dial Transplant199813847499568837
PubMed Web of Science ®Google Scholar
MercadenteSGebbiaVMarrazzoAAnemia in cancer: pathophysiology and treatmentCancer Treat Rev20002530311
Web of Science ®Google Scholar
MillerCBJonesRJPiantadosiSDecreased erythropoietin response in patients with the anemia of cancerN Engl J Med19903221689922342534
PubMed Web of Science ®Google Scholar
MittelmanMZeidmanAFradinZRecombinant human erythropoietin in the treatment of multiple myeloma-associated anemiaActa Haematol199798204109401498
PubMed Web of Science ®Google Scholar
MittelmanMNeumannDPeledAErythropoietin induces tumor regression and antitumor immune responses in murine myeloma modelsProc Natl Acad Sci USA2001985181611309490
PubMed Web of Science ®Google Scholar
MittelmanMZeidmanAKanterPErythropoietin has an anti-myeloma effect – a hypothesis based on a clinical observation supported by animal studiesEur J Haematol2004721556514962233
PubMed Web of Science ®Google Scholar
MoulletISallesGKettererNFrequency and significance of anemia in non-Hodgkin’s lymphoma patientsAnn Oncol199891109159834824
PubMed Web of Science ®Google Scholar
NowrousianMRPathophysiology of cancer-related anemiaRecombinant human erythropoietin in clinical oncology2002New YorkSpringer Medicine
Google Scholar
NemethEGanzTRegulation of iron metabolism by hepcidinAnn Rev Nutr2006263234216848710
PubMed Web of Science ®Google Scholar
OsterborgABrandbergYMolostovaVfor the Epoetin Beta Hematology Study GroupRandomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignanciesJ Clin Oncol2002201024869412011126
PubMed Web of Science ®Google Scholar
OsterborgABrandbergYHedenusMImpact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized studyBr J Haematol2005129206915813848
PubMed Web of Science ®Google Scholar
PangalisGASiakantarisMAngelpolouMKDownstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietinHematologica2002875006
PubMed Web of Science ®Google Scholar
PunnonenKIrjalaKRajamakiASerum transferrin receptor and its ration to serum ferritin in the diagnosis of iron deficiencyBlood1997891052579028338
PubMed Web of Science ®Google Scholar
QuirtIRobesonCLauCYEpoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapyJ Clin Oncol20011941263411689580
PubMed Web of Science ®Google Scholar
RoyCNAndrewsNCAnemia of inflammation: the hepcidin linkCurr Opin Haematol20051210711
PubMed Web of Science ®Google Scholar
SeidenfeldJPiperMFlammCEpoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trialsJ Natl Cancer Inst20019312041411504766
PubMed Web of Science ®Google Scholar
SeidenfeldJPiperMAronsonNSystematic review of controlled trials on erythropoietin to support evidence-based guidelinesOncology (Williston Park)2002169 Suppl 101718812380968
PubMed Web of Science ®Google Scholar
SepandjFJindalKWestMEconomic appraisal of maintenance parenteral iron administration in treatment of anemia in chronic haemodialysis patientsNeprol Dial Transplant19961131922
PubMed Web of Science ®Google Scholar
SiakantarisMPAngelopoulouMKVassilakopoulosTPCorrection of disease related anemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain responseLeuk Lymphoma2000401–2141711426615
PubMed Web of Science ®Google Scholar
SteensmaDPMolinaRSloanJAPhase III study of two different dosing schedules of erythropoietin in anemic patients with cancerJ Clin Oncol20062410798916505427
PubMed Web of Science ®Google Scholar
StrausDJTestaMASarokhanBJQuality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignanciesCancer200610719091716977654
PubMed Web of Science ®Google Scholar
ThomasCKirschbaumABoehmDThe diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapyMed Oncol200623233616645227
PubMed Web of Science ®Google Scholar
TonelliMBlakePGMuirheadNPredictors of erythropoietin responsiveness in chronic hemodialysis patientsAsaio J20014782511199321
PubMed Web of Science ®Google Scholar
Van BelleSParidaensREversGComparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening toolSupport Care Cancer2005132465415549424
PubMed Web of Science ®Google Scholar
VansteenkisteJWautersIThe use of darbepoetin alfa for the treatment of chemotherapy-induced anemiaExpert Opin Pharmacother200564294015794734
PubMed Web of Science ®Google Scholar
WitzigTESilbersteinPTLoprinziCLPhase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapyJ Clin Oncol20052326061715452187
PubMed Web of Science ®Google Scholar
YellenSBCellaDFWebsterKMeasuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJ Pain Symptom Manage19971363749095563
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Managing anemia in lymphoma and multiple myeloma

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Managing anemia in lymphoma and multiple myeloma

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date